



## Mersana Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 20, 2017

CAMBRIDGE, Mass., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its proprietary Dolaflexin® platform, today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 10, 2018 at 4:00 p.m. PT.

A live webcast of the presentation will be available on the Investors & Media section of Mersana's website at [www.mersana.com](http://www.mersana.com). An archived replay will be available for approximately 60 days following the presentation.

### About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to patients. Mersana's lead product candidate, XMT-1522, is in Phase 1 clinical trials in patients with advanced tumors expressing HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company's second product candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and other cancers.

In addition, multiple partners are using Mersana's platform to advance their ADC pipelines.

### Forward-Looking Statements

This press release contains "forward-looking" statements within the meaning of federal securities laws. These forward-looking statements are not statements of historical facts and are based on management's beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning the design of its clinical trials. Forward-looking statements generally can be identified by terms such as "anticipates," "believes," "could," "seeks," "estimates," "intends," "may," "plans," "potential," "predicts," "projects," "should," "will," "would" or similar expressions and the negatives of those terms. Forward-looking statements represent management's beliefs and assumptions only as of the date of this presentation. The Company's operations involve risks and uncertainties, many of which are outside its control, and any one of which, or combination of which, could materially affect its results of operations and whether the forward-looking statements ultimately prove to be correct. Factors that may materially affect the Company's results of operations include, among other things, that preclinical testing may not be predictive of the results or success of ongoing or later preclinical or clinical trials and that the development of the Company's product candidates will take longer and/or cost more than planned, as well as those listed in the Company's Quarterly Report on Form 10-Q filed on November 13, 2017 with the Securities and Exchange Commission ("SEC"). Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Copies of the Company's our Quarterly Report on Form 10-Q and our other SEC filings are available by visiting EDGAR on the SEC website at <http://www.sec.gov>.

### Contacts:

Media Contact  
Paul Kidwell, 617-680-1088  
[paulkidwell@mersana.com](mailto:paulkidwell@mersana.com)

or

Investors Contact  
Stern Investor Relations, Inc.  
Christina Tartaglia, 212-362-1200  
[christina@sternir.com](mailto:christina@sternir.com)

[Primary Logo](#)

Source: Mersana Therapeutics, Inc.